Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
MedCity News10d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
At the time of the trial readout, Martin Lange, executive vice president and head of development at Novo Nordisk, said the results indicate the drug’s weight-lowering potential, adding that more ...